title: Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling.
abstract: Treatment of children's acute lymphoblastic leukemia has been at the forefront of conventional chemotherapy development. Despite outstanding results in long-term survival of acute lymphoblastic leukemia, development of therapies for acute myeloid leukemia (AML) have lagged behind. AML in children demonstrate similar long-term survival compared with adults 18-65 years of age: 40-50% overall long-term survival. AML is a heterogeneous disease in both adults and children, but the presence of recurrent chromosome translocations and mutations in children are lower than in adult AML. In particular, patients without chromosome aberrancies have been examined for stratification through examination of gene expression. The paper from Baglobind and coauthors proposes a useful prognostication by gene-expression analysis of 75 gene pairs in 40% of patient cases, accurately discriminating mixed lineage leukemia (MLL) gene rearrangement, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)-positive AML. Gene-expression analysis of AML has provided an important research tool for uncovering information about AML biology that can be used for the development of novel therapies.
authors.affiliation: University of Bergen, Institute of Medicine, Hematology Section, Department of Internal Medicine, Haukeland University Hospital, Jonas Liesvei 65, Bergen 5021, Norway. bjorn.gjertsen@med.uib.no
authors.forename: Bjørn Tore
authors.initials: BT
authors.lastname: Gjertsen